Aktienanalyse zu Kiniksa Pharmaceuticals Ltd (KNSA)KNSAKiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Kiniksa Pharmaceuticals Ltd (KNSA) is a good buy right now due to its recent strong performance and positive outlook. The current price is $79.78, and the company reported a remarkable 55% year-over-year revenue growth to $243.6 million for Q2 2026, which has led to an upward revision of its full-year revenue guidance to between $980 million and $995 million. Additionally, the RSI is at 78.74, indicating strong momentum, while the forward P/E ratio is 59.52, suggesting growth potential despite high valuation. The main risk is the high forward P/E ratio, which could indicate overvaluation if growth does not meet expectations.

4 analysts cover KNSA: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 53.50.